Apricus Biosciences Inc. appoints Richard Pascoe as CEO and to the board of directors. Pascoe moves from Somaxon Pharmaceuticals Inc., where as CEO he led the firm through FDA approval and commercialization of the Silenor drug indicated for insomnia and the firm’s recent sale(see “Somaxon finds buyer,” p. 8). Pascoe previously was senior VP and chief operating officer at Ariad Pharmaceuticals Inc., and senior VP of marketing and sales at King Pharmaceuticals Inc. Interim Apricus CEO Steve Martin resumes his responsibilities as senior VP and chief financial officer, the San Diego-based firm said March 18. Apricus develops OTC and Rx treatments for male and female sexual health, in transdermal, oral and subcutaneous forms ([A#05110905009]).
K. Anji Reddy, founder and chairman of Dr. Reddy's Laboratories Ltd., died March 15 in Hyderabad, India. A graduate...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?